Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
8,600
Employees8,600
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
8,600
Employees8,600

ILMN Key Statistics

Market cap
20.57B
Market cap20.57B
Price-Earnings ratio
23.38
Price-Earnings ratio23.38
Dividend yield
Dividend yield
Average volume
2.53M
Average volume2.53M
High today
$134.76
High today$134.76
Low today
$127.01
Low today$127.01
Open price
$127.18
Open price$127.18
Volume
4.01M
Volume4.01M
52 Week high
$155.53
52 Week high$155.53
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $134.57, with a market capitalization of 20.57B. The stock trades at a price-to-earnings (P/E) ratio of 23.38.

On 2026-02-28, Illumina(ILMN) stock moved within a range of $127.01 to $134.76. With shares now at $134.57, the stock is trading +6.0% above its intraday low and -0.1% below the session's peak.

Trading activity shows a volume of 4.01M, compared to an average daily volume of 2.53M.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

ILMN News

TipRanks 16h
Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating

Illumina, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Hold rati...

TipRanks 18h
Roche genome pricing positive for Illumina, says TD Cowen

TD Cowen analyst Dan Brennan says Roche (RHHBY) yesterday announced the consumables price for the Xpandomer-based nanopore sequencer, Axelios, at $150 per genom...

Simply Wall St 1d
Assessing Illumina Valuation After Recent Share Price Momentum Shifts

Illumina (ILMN) is back in focus for investors after recent trading moves, with the stock showing mixed performance across different time frames and a meaningfu...

Assessing Illumina Valuation After Recent Share Price Momentum Shifts

Analyst ratings

43%

of 23 ratings
Buy
43.5%
Hold
43.5%
Sell
13%

More ILMN News

Simply Wall St 3d
Illumina Genome Push Raises Questions On Growth, Adoption And Valuation

Illumina (NasdaqGS:ILMN) introduced TruPath Genome, a whole genome sequencing solution designed to improve accuracy, workflow efficiency, and cost effectiveness...

Illumina Genome Push Raises Questions On Growth, Adoption And Valuation
TipRanks 3d
Top Illumina Executive Makes Notable Insider Stock Move

New insider activity at Illumina ( (ILMN) ) has taken place on February 24, 2026. Illumina’s Chief Legal Officer, Scott M. Davies, has trimmed his stake in the...

Simply Wall St 4d
The Bull Case For Illumina Could Change Following Buybacks And NovaSeq X Roadmap Reveal – Learn Why

In the months to 11 February 2026, Illumina completed a share repurchase program, buying back 9,958,000 shares, or 6.31% of its stock, for US$1.02 billion, whil...

The Bull Case For Illumina Could Change Following Buybacks And NovaSeq X Roadmap Reveal – Learn Why

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.